MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Operating margin 2016–2024
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) operating margin by fiscal year — reported operating income divided by reported revenue.
-2243.9%FY2024 · since FY2016: -4245.4% → -2243.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -2243.9% | -1498.4 pp |
| FY2023 | -745.5% | +73769.7 pp |
| FY2022 | -74515.2% | -58893.0 pp |
| FY2021 | -15622.1% | +11330.3 pp |
| FY2020 | -26952.5% | -11152.0 pp |
| FY2019 | -15800.4% | -6015.7 pp |
| FY2018 | -9784.8% | — |
| FY2016 | -4245.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More MTNB financial trends
MTNB RevenueMTNB Net incomeMTNB Net marginMTNB Gross profitMTNB Gross marginMTNB Operating incomeMTNB Operating cash flowMTNB Free cash flowMTNB Capital expendituresMTNB Return on equityMTNB Stock buybacksMTNB Dividends paidMTNB Total assetsMTNB Total liabilitiesMTNB Shareholders’ equityMTNB overview →